PL-100, a novel HIV-1 protease inhibitor displaying a high genetic barrier to resistance: An in vitro selection study

Journal of Medical Virology

Volumn 80, Issue 12, 2008, Pages 2053-2063

  Dandache, Serge ^a,d   Coburn, Craig A ^b   Oliveira, Maureen ^c   Allison, Timothy J ^b   Holloway, M Katharine ^b   Wu, Jinzi J ^a   Stranix, Brent R ^a   Panchal, Chandra ^a   Wainberg, Mark A ^c   Vacca, Joseph P ^b  

^a Ambrilia Biopharma Inc   (Canada)

^b MERCK RESEARCH LABORATORIES   (United States)

^c MCGILL UNIVERSITY   (Canada)

^d NONE   (Canada)

Author keywords

Genetic barrier; HIV; Mutation; Protease inhibitor; Resistance

Indexed keywords

AMPRENAVIR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ATAZANAVIR; GAG PROTEIN; INDINAVIR; LOPINAVIR; NELFINAVIR; PL 100; PROTEINASE; PROTEINASE INHIBITOR; SAQUINAVIR; UNCLASSIFIED DRUG;

ANTIVIRAL RESISTANCE; ARTICLE; CONTROLLED STUDY; CROSS RESISTANCE; CRYSTAL STRUCTURE; DRUG STRUCTURE; ENZYME ACTIVE SITE; ENZYME ACTIVITY; GENOTYPE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; MONONUCLEAR CELL; NONHUMAN; PHENOTYPE; SITE DIRECTED MUTAGENESIS; VIROGENESIS; VIRUS MUTATION; VIRUS REPLICATION; VIRUS STRAIN; X RAY CRYSTALLOGRAPHY;

CARBAMATES; CATALYTIC DOMAIN; CELLS, CULTURED; DRUG RESISTANCE, VIRAL; HIV PROTEASE; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; LEUKOCYTES, MONONUCLEAR; MODELS, MOLECULAR; MUTAGENESIS, SITE-DIRECTED; MUTATION, MISSENSE; PROTEIN STRUCTURE, TERTIARY; SULFONAMIDES;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 57349140800     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.21329     Document Type: Article

References (44)

1. Adachi A, Gendelman HE, Koenig S, Folks T, Willey R, Rabson A, Martin MA. 1986. Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone. J Virol 59:284-291.
2. Charpentier C, Nora T, Tenaillon O, Clavel F, Hance AJ. 2006. Extensive recombination among human immunodeficiency virus type 1 quasispecies makes an important contribution to viral diversity in individual patients. J Virol 80:2472-2482.
3. Chen Z, Li Y, Chen E, Hall DL, Darke PL, Culberson C, Shafer JA, Kuo LC. 1994. Crystal structure at 1.9-A resolution of human immunodeficiency virus (HIV) II protease complexed with L-735,524, an orally bioavailable inhibitor of the HIV proteases. J Biol Chem 269:26344-26348.
4. Clemente JC, Moose RE, Hemrajani R, Whitford LR, Govindasamy L, Reutzel R, McKenna R, Agbandje-McKenna M, Goodenow MM, Dunn BM. 2004. Comparing the accumulation of active- and nonactive-site mutations in the HIV-1 protease. Biochemistry 43:12141-12151.
5. Collins JR, Burt SK, Erickson JW. 1995. Flap opening in HIV-1 protease simulated by 'activated' molecular dynamics. Nat Struct Biol 2:334-338.
6. Condra JH, Emini EA. 1997. Preventing HIV-1 drug resistance. Sci Med 4:14-23.
7. Condra JH, Schleif WA, Blahy OM, Gabryelski LJ, Graham DJ, Quintero JC, Rhodes A, Robbins HL, Roth E, Shivaprakash M, Titus D, Yang T, Tepplert H, Squires KE, Deutsch PJ, Emini EA. 1995. In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature 374:569-571.
8. Condra JH, Holder DJ, Schleif WA, Blahy OM, Danovich RM, Gabryelski LJ, Graham DJ, Laird D, Quintero JC, Rhodes A, Robbins HL, Roth E, Shivaprakash M, Yang T, Chodakewitz JA, Deutsch PJ, Leavitt RY, Massari FE, Mellors JW, Squires KE, Steigbigel RT, Teppler H, Emini EA. 1996. Genetic correlates of in vivo viral resistance to indinavir, a human immunodeficiency virus type 1 protease inhibitor. J Virol 70:8270-8276.
9. Dandache S, Sevigny G, Yelle J, Stranix BR, Parkin N, Schapiro JM, Wainberg MA, Wu JJ. 2007. In vitro antiviral activity and cross-resistance profile of PL-100, a novel protease inhibitor of human immunodeficiency virus type 1. Antimicrob Agents Chemother 51:4036-4043.
10. Division of AIDS NIAID. 1997. HIV drug susceptibility assay - DAIDS virology manual for HIV laboratories. In: services USDoHaH, editor. Washington, DC: Publication NIH-97-3828. pp. 78-89.
11. Doyon L, Croteau G, Thibeault D, Poulin F, Pilote L, Lamarre D. 1996. Second locus involved in human immunodeficiency virus type 1 resistance to protease inhibitors. J Virol 70:3763-3769.
12. Foulkes JE, Prabu-Jeyabalan M, Cooper D, Henderson GJ, Harris J, Swanstrom R, Schiffer CA. 2006. Role of invariant Thr80 in human immunodeficiency virus type 1 protease structure, function, and viral infectivity. J Virol 80:6906-6916.
13. Gulick T. 1997. Introduction of DNA into mammalian cells-Transfection Using DEAE-Dextran. In: Frederick M, Ausubel RB, Kingston RE, Moore DD, Seidman JG, Smith JA, Struhl K, editors. Current protocols in molecular biology. Somerset, NJ: John Wiley& Sons, inc. pp. 9.2.1-9.2.10.
14. Haertle T, Carrera CJ, Wasson DB, Sowers LC, Richman DD, Carson DA. 1988. Metabolism and anti-human immunodeficiency virus-1 activity of 2-halo-2′,3′-dideoxyadenosine derivatives. J Biol Chem 263:5870-5875.
15. Halgren TA. 1996. Merck molecular force field. I. Basis, form, scope, parameterization, and performance of MMFF94. J Comput Chem 17:490-519.
16. Halgren TA, Nachbar RB. 1996. Merck molecular force field. IV. conformational energies and geometries for MMFF94. J Comput Chem 17:587-615.
17. Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM, Markowitz M. 1995. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 373:123-126.
18. Jacobsen H, Yasargil K, Winslow DL, Craig JC, Krohn A, Duncan IB, Mous J. 1995. Characterization of human immunodeficiency virus type 1 mutants with decreased sensitivity to proteinase inhibitor Ro31-8959. Virology 206:527-534.
19. Johnson VA, Byington RE. 1990. Quantitative assays for virus infectivity. In: Aldovivi A, Warker BD, editors. Techniques in HIV research. New York: Stockton Press. pp. 71-76.
20. Johnson VA, Brun-Vezinet F, Clotet B, Gunthard HF, Kuritzkes DR, Pillay D, Schapiro JM, Richman DD. 2007. Update of the drug resistance mutations in HIV-1: 2007. Top HIV Med 15:119-125.
21. Kohl NE, Emini EA, Schleif WA, Davis LJ, Heimbach JC, Dixon RA, Scolnick EM, Sigal IS. 1988. Active human immunodeficiency virus protease is required for viral infectivity. Proc Natl Acad Sci USA 85:4686-4690.
22. Little SJ, Holte S, Routy JP, Daar ES, Markowitz M, Collier AC, Koup RA, Mellors JW, Connick E, Conway B, Kilby M, Wang L, Whitcomb JM, Hellmann NS, Richman DD. 2002. Antiretroviral-drug resistance among patients recently infected with HIV. N Engl J Med 347:385-394.
23. Maguire MF, Guinea R, Griffin P, Macmanus S, Elston RC, Wolfram J, Richards N, Hanlon MH, Porter DJ, Wrin T, Parkin N, Tisdale M, Furfine E, Petropoulos C, Snowden BW, Kleim JP. 2002. Changes in human immunodeficiency virus type 1 Gag at positions L449 and P453 are linked to I50V protease mutants in vivo and cause reduction of sensitivity to amprenavir and improved viral fitness in vitro. J Virol 76:7398-7406.
24. Malet I, Roquebert B, Dalban C, Wirden M, Amellal B, Agher R, Simon A, Katlama C, Costagliola D, Calvez V, Marcelin AG. 2007. Association of Gag cleavage sites to protease mutations and to virological response in HIV-1 treated patients. J Infect 54:367-374.
25. Mohamadi F, Richards NGJ, Guida WC, Liskamp R, Lipton M, Caufiled C, Chang G, Hendrickson T, Still WC. 1990. MacroModel - An integrated software system for modeling organic and bioorganic molecules using molecular mechanics. J Comput Chem 11:440-467.
26. Nalam MN, Peeters A, Jonckers TH, Dierynck I, Schiffer CA. 2007. Crystal structure of lysine sulfonamide inhibitor reveals the displacement of the conserved flap water molecule in human immunodeficiency virus type 1 protease. J Virol 81:9512-9518.
27. Palella FJ, Jr., Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, Aschman DJ, Holmberg SD. 1998. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 338:853-860.
28. Partaledis JA, Yamaguchi K, Tisdale M, Blair EE, Falcione C, Maschera B, Myers RE, Pazhanisamy S, Futer O, Cullinan AB, et al. 1995. In vitro selection and characterization of human immunodeficiency virus type 1 (HIV-1) isolates with reduced sensitivity to hydroxyethylamino sulfonamide inhibitors of HIV-1 aspartyl protease. J Virol 69:5228-5235.
29. Patick AK, Duran M, Cao Y, Shugarts D, Keller MR, Mazabel E, Knowles M, Chapman S, Kuritzkes DR, Markowitz M. 1998. Genotypic and phenotypic characterization of human immunodeficiency virus type 1 variants isolated from patients treated with the protease inhibitor nelfinavir. Antimicrob Agents Chemother 42:2637-2644.
30. Pauwels R, Balzarini J, Baba M, Snoeck R, Schols D, Herdewijn P, Desmyter J, De Clercq E. 1988. Rapid and automated tetrazolium-based colorimetric assay for the detection of anti-HIV compounds. J Virol Methods 20:309-321.
31. Pazhanisamy S, Partaledis JA, Rao BG, Livingston DJ. 1998. In vitro selection and characterization of VX-478 resistant HIV-1 variants. Adv Exp Med Biol 436:75-83.
32. Piana S, Carloni P, Rothlisberger U. 2002. Drug resistance in HIV-1 protease: Flexibility-assisted mechanism of compensatory mutations. Protein Sci 11:2393-2402.
33. Popovic M, Read-Connole E, Gallo RC. 1984. T4 positive human neoplastic cell lines susceptible to and permissive for HTLV-III. Lancet 2:1472-1473.
34. Richar N, Quan Y, Salomon H, Hsu M, Bedard J, Harrigan PR, Rando R, Mansour T, Bowlin TL, Wainberg MA. 1999. Selection and characterization of HIV-1 variants resistant to the (+) and (-) enantiomers of 2′-deoxy-3′- oxa-4′-thiocytidine (dOTC). Antivir Ther 4:171-177.
35. Salomon H, Belmonte A, Nguyen K, Gu Z, Gelfand M, Wainberg MA. 1994. Comparison of cord blood and peripheral blood mononuclear cells as targets for viral isolation and drug sensitivity studies involving human immunodeficiency virus type 1. J Clin Microbiol 32:2000-2002.
36. Salomon H, Wainberg MA, Brenner B, Quan Y, Rouleau D, Cote P, LeBlanc R, Lefebvre E, Spira B, Tsoukas C, Sekaly RP, Conway B, Mayers D, Routy JP. 2000. Prevalence of HIV-1 resistant to antiretroviral drugs in 81 individuals newly infected by sexual contact or injecting drug use. Investigators of the Quebec Primary Infection Study. AIDS 14:F17-23.
37. Stachel SJ, Coburn CA, Sankaranarayanan S, Price EA, Wu G, Crouthamel M, Pietrak BL, Huang Q, Lineberger J, Espeseth AS, Jin L, Ellis J, Holloway MK, Munshi S, Allison T, Hazuda D, Simon AJ, Graham SL, Vacca JP. 2006. Macrocyclic inhibitors of beta-secretase: Functional activity in an animal model. J Med Chem 49:6147-6150.
38. Steain MC, Wang B, Dwyer DE, Saksena NK. 2004. HIV-1 co-infection, superinfection and recombination. Sex Health 1:239-250.
39. Svicher V, Ceccherini-Silberstein F, Erba F, Santoro M, Gori C, Bellocchi MC, Giannella S, Trotta MP, Monforte A, Antinori A, Perno CF. 2005. Novel human immunodeficiency virus type 1 protease mutations potentially involved in resistance to protease inhibitors. Antimicrob Agents Chemother 49:2015-2025.
40. Swanstrom R, Erona J. 2000. Human immunodeficiency virus type-1 protease inhibitors: Therapeutic successes and failures, suppression and resistance. Pharmacol Ther 86:145-170.
41. Vittinghoff E, Scheer S, O'Malley P, Colfax G, Holmberg SD, Buchbinder SP. 1999. Combination antiretroviral therapy and recent declines in AIDS incidence and mortality. J Infect Dis 179:717-720.
42. Vondrasek J, Wlodawer A. 1997. Database of HIV proteinase structures. Trends Biochem Sci 22:183.
43. Wei X, Ghosh SK, Taylor ME, Johnson VA, Emini EA, Deutsch P, Lifson JD, Bonhoeffer S, Nowak MA, Hahn BH, et al. 1995. Viral dynamics in human immunodeficiency virus type 1 infection. Nature 373:117-122.
44. Yeni PG, Hammer SM, Hirsch MS, Saag MS, Schechter M, Carpenter CC, Fischl MA, Gatell JM, Gazzard BG, Jacobsen DM, Katzenstein DA, Montaner JS, Richman DD, Schooley RT, Thompson MA, Vella S, Volberding PA. 2004. Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society-USA Panel. JAMA 292:251-265.